CollPlant Biotechnologies (CLGN) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Regentis Biomaterials is the larger company by market cap ($11.2 million vs $6.6 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLGN | RGNT |
|---|---|---|
| Share price | $3.51 | $1.60 |
| Market cap | $6.64M | $11.24M |
| 1-day change | -11.59% | -5.88% |
| YTD return | — | -76.26% |
| EPS (TTM) | $-9.33 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.80 | $15.50 |
| 52-week low | $2.64 | $1.23 |
| Distance from 52-week high | -86.90% | -89.68% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +525.00% |
| Average volume | 352.86K | 76.68K |
| Shares outstanding | 1.89M | 7.02M |
| Employees | 39 | — |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Health Care · Industrial Specialties · 39 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Health Care · Industrial Specialties
CLGN vs RGNT FAQ
Which is bigger, CollPlant Biotechnologies or Regentis Biomaterials?
Regentis Biomaterials (RGNT) is larger, with a market capitalization of $11.24M compared with $6.64M for CollPlant Biotechnologies (CLGN).
Are CollPlant Biotechnologies and Regentis Biomaterials in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.